Globally, BioPharma companies have begun to improve their analytical divisions in order to remain competitive in the market, as well as meet stringent regulatory requirements. In India, the market is focused on the manufacture of biosimilars—replicas of the original innovator protein therapeutic molecules. Due to different processes employed, biosimilars are not an exact copy of the innovator protein, but have very similar efficacy to the originator molecule. Several analytical techniques, such as LC, LC/MS and spectroscopy, have become important and valuable tools in demonstrating similarities between the innovator and its biosimilar product.
Exploring BioPharma innovation and expansion in India
Seeking to address the unique needs of the Indian BioPharma industry, Agilent hosted a BioPharma Workflow Solution workshop at its state-of-the-art Bangalore site to explore biosimilar characterization. The goal of the workshop was to demonstrate Agilent’s BioPharma Workflow solutions to customers involved in characterization of biopharmaceuticals from discovery to development and in quality control. The event was well attended by thought leaders from the emerging BioPharma industy in India, and provided a robust platform for collaboration with industry experts.
Two-day workshop provides opportunities for learning, idea sharing, and collaboration
Figure 1. Biopharma workshop sessions were held at the Agilent Center of Excellence lab (left) and at the Market development Centre India (right).
Figure 2. Results from the demonstrations of some workflows during workshop: (A) Charge variant analysis; (B) Size exclusion analysis of ADC; (C) Reversed-phase LCMS analysis of mAb; and (D) Drug antibody ratio analysis using Agilent’s DAR calculator.
More than 25 delegates attended the two-day workshop, which included experts in R&D, method development scientists, downstream scientists, and QA/QC analysts from participating companies. Following an introductory session, topics related to characterization of biomolecules were presented. An engaging Q&A session provided an opportunity for all attendees to share ideas and learnings. As monoclonal antibodies(mAbs) command a major share in market of the biotherapeutics, the primary focus of the sessions was the characterization of protein molecules. Attendees participated in multiple activities conducted in the laboratory (Figure 1). Highlights included examples and application of workflows for peptide mapping, aggregate analysis, change variant analysis, and intact analysis.
Peptide mapping workflow demonstrated on Agilent 1290 Infinity II LC system
Size exclusion chromatography delivers superior aggregate analysis
Aggregate analysis is an important critical quality attribute (CQA) of protein biotherapeutics. The gold standard for analysis of aggregates in the sample is size exclusion chromatography (SEC). Participants in the workshop experienced a live demo of mAb sample analysis using the newly introduced Agilent AdvanceBio SEC column with Agilent 1260 Infinity II BioInert LC system.
Charge variant analysis is another CQA for mAbs. The workflow involves using an ion exchange (IEX) column to separate charge variants using either salt gradient or pH gradient to elute out the different variants from Agilent Bio-IEX columns. Charge variants can occur in molecule due to modifications during storage or handling, such as oxidation and deamidation.
In this workshop, charge variants from one of the biosimilar mAbs were demonstrated using the Agilent 1290 Infinity II 2D-LC Solution. Ion exchange column was in 1st dimension followed by reverse phase in 2nd dimension. Data was presented on 2D-LC/MS for the same molecule. An ideal tool for generating pH or ionic strength gradients for protein charge variant separation is Agilent Buffer Advisor Software.
LC/MS—Best choice for intact and fragment analysis
Leading professor delivers insightful talk on challenges faced by Indian BioPharma companies
Building upon the workshop collaborations, a lecture by guest Prof. Anurag Rathore from the Indian Institute of Technology Delhi was organized. Prof. Rathore is a well-regarded thought leader in the field of BioPharma and is renowned for using quality by design (QbD) principles in BioPharma related processes. His talk focused on the characterization of mAbs using different biophysical techniques and applying QbD principles for process enhancement during characterizations. Prof. Rathore expanded on the BioPharma landscape of India and the challenges faced by Indian BioPharma companies in development of biosimilars.
Agilent offers ongoing workshops, seminars, and learning opportunities
This latest Agilent collaboration with industry thought leaders and customers was very well received. Participants gained new insights and explored comprehensive workflow solutions from Agilent for the analysis of biomolecules. Ongoing Biopharma workshops will cover topics such as CE, CEMS, and troubleshooting instruments. To learn more about Agilent’s full line-up of LC, LC/MS, and Q-TOF solutions, as well as MassHunter software, contact an Agilent representative today.
Stay informed about the applications that are important to you
Biopharma workshop sessions were held at the Agilent Center of Excellence lab (left) and at the Market development Centre India (right).
Results from the demonstrations of some workflows during workshop: (A) Charge variant analysis; (B) Size exclusion analysis of ADC; (C) Reversed-phase LCMS analysis of mAb; and (D) Drug antibody ratio analysis using Agilent’s DAR calculator.